Real-time Margin Dune's tissue characterization technology enables real-time cancer margin assessment during lumpectomies, with MarginProbe and reposable biopsy capabilities and a history of in-man trials. This positions hospitals and surgical centers as key buyers aiming to reduce re-excision rates and shorten procedure times. BD play: target surgical oncology, radiology, and pathology decision-makers; build ROI cases and pilot programs.

Dilon Channel Dune asset sales to Dilon Diagnostics in 2020 indicate a potential channel for collaboration or licensing within Dilon's customer base and gamma probe ecosystem. Sales opportunities include licensing MarginProbe IP to Dilon, bundling with gamma probe offerings, or cross-selling to breast cancer centers, with ongoing service and support contracts. Next steps: approach Dilon with licensing or co-marketing proposals and map overlapping customers.

Clinical Growth The history of trials and RF platform expansion suggests readiness to validate new indications and sites. Leverage multi-site clinical partnerships with hospitals and academic centers to broaden adoption of MarginProbe and RF spectroscopy, generating robust outcomes data to support pricing, reimbursement, and broader market acceptance.

Nimble Support As a smaller company, Dune can offer high-touch installation, training, and post-sale support that appeals to health systems seeking responsive vendors. Sales strategy should emphasize comprehensive service agreements, rapid onboarding, remote diagnostics, and dedicated customer support to accelerate procurement and adoption.

Licensing Partnerships The MarginProbe and RF spectroscopy platforms have potential for OEM partnerships with device makers in intraoperative imaging, biopsy devices, or oncology diagnostics, as well as international distribution opportunities. Explore licensing, co-development, and distribution deals to scale reach beyond current footprint.